Myokardia/BMS cardiac myosin inhibitor
FIC, oral, QD, cardiac myosin inhibitor FDA-approved for obstructive HCM opt. of HTS hit for sarcomere activity inhibition mavacamten (MYK461, CAMZYOS) Myokardia, Brisbane, CA; Bristol Myers Squibb, New York, NY
Molecules of the Month - 2022 Molecules of the Year Nominees
- BMS TYK2 inhibitor
- Mirati/Array/Pfizer KRAS(G12D) inhibitor
- Madrigal THRβ-selective agonist
- GBT/Pfizer HbS polymerization inhibitor
- Myokardia/BMS cardiac myosin inhibitor
- Kura Oncology menin-MLL1 inhibitor
- LEO Pharma IL-17A modulator
- YourChoice/UMN RAR-α antagonist
- Cerevel/Pfizer M4 positive allosteric modulator
- ChemoCentryx C5aR antagonist
- BMS TYK2 inhibitor
- Mirati/Array/Pfizer KRAS(G12D) inhibitor
- Madrigal THRβ-selective agonist
- GBT/Pfizer HbS polymerization inhibitor
- Myokardia/BMS cardiac myosin inhibitor
- Kura Oncology menin-MLL1 inhibitor
- LEO Pharma IL-17A modulator
- YourChoice/UMN RAR-α antagonist
- Cerevel/Pfizer M4 positive allosteric modulator
- ChemoCentryx C5aR antagonist